|
1 Indications And Usage Perjeta Is A Her2/neu Receptor Antagonist Indicated For: Use In Combination With Trastuzumab And Docetaxel For Treatment Of Patients With Her2-Positive Metastatic Breast Cancer (Mbc) Who Have Not Received Prior Anti-Her2 Therapy Or Chemotherapy For Metastatic Disease. ( 1.1 ) Use In Combination With Trastuzumab And Chemotherapy As Neoadjuvant Treatment Of Patients With Her2-Positive, Locally Advanced, Inflammatory, Or Early Stage Breast Cancer (Either Greater Than 2 Cm In Diameter Or Node Positive) As Part Of A Complete Treatment Regimen For Early Breast Cancer. ( 1.2 , 2.2 , 14.2 ) Adjuvant Treatment Of Patients With Her2-Positive Early Breast Cancer At High Risk Of Recurrence ( 1.2 , 2.2 , 14.3 ) 1.1 Metastatic Breast Cancer (Mbc) Perjeta Is Indicated For Use In Combination With Trastuzumab And Docetaxel For The Treatment Of Patients With Her2-Positive Metastatic Breast Cancer Who Have Not Received Prior Anti-Her2 Therapy Or Chemotherapy For Metastatic Disease [See Dosage And Administration (2.2) And Clinical Studies (14.1) ] . 1.2 Early Breast Cancer (Ebc) Perjeta Is Indicated For Use In Combination With Trastuzumab And Chemotherapy For The Neoadjuvant Treatment Of Patients With Her2-Positive, Locally Advanced, Inflammatory, Or Early Stage Breast Cancer (Either Greater Than 2 Cm In Diameter Or Node Positive) As Part Of A Complete Treatment Regimen For Early Breast Cancer [See Dosage And Administration (2.2) And Clinical Studies (14.2) ] . The Adjuvant Treatment Of Patients With Her2-Positive Early Breast Cancer At High Risk Of Recurrence [See Dosage And Administration (2.2) And Clinical Studies (14.3) ] .
|